A Randomised, Double-Blind, Placebo-Controlled, Dose Escalation, Safety, Tolerability and Pharmacokinetics Study of Single Ascending and Multiple Doses of GWP42006 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 06 May 2015
Price : $35 *
At a glance
- Drugs Cannabidivarin (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors GW Pharmaceuticals
- 06 May 2015 Positive results published in a GW Pharmaceuticals media release.
- 30 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Aug 2013 New source identified and integrated: ClinicalTrials.gov record.